Search results
Results from the Think 24/7 Content Network
MDAI (5,6-methylenedioxy-2-aminoindane) is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non- neurotoxic and highly selective serotonin releasing agent (SSRA) in vitro and produces entactogen effects in humans.
3,4-Methylenedioxyamphetamine (also known as MDA and sass) is an empathogen-entactogen, psychostimulant, and psychedelic drug of the amphetamine family that is encountered mainly as a recreational drug. In its pharmacology, MDA is a serotonin–norepinephrine–dopamine releasing agent (SNDRA). In most countries, the drug is a controlled ...
This class of drugs are mimics of serotonin that activate 5-HT receptor subtypes that release norepinephrine and dopamine. 2C-B-BZP. 3-Chlorophenylpiperazine, meta-Chlorophenylpiperazine, mCPP. 4-Fluorophenylpiperazine, para-Fluorophenylpiperazine, pFPP, 4-FPP, Fluoperazine, Flipiperazine.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
5-Iodo-2-aminoindane ( 5-IAI) is a drug which acts as a releasing agent of serotonin, norepinephrine, and dopamine. [2] It was developed in the 1990s by a team led by David E. Nichols at Purdue University. [3] 5-IAI fully substitutes for MDMA in rodents and is a putative entactogen in humans. [3] Unlike related aminoindane derivatives like MDAI ...
AOL latest headlines, entertainment, sports, articles for business, health and world news.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Donate; Pages for logged out editors learn more
David Earl Nichols (born December 23, 1944, Covington, Kentucky) is an American pharmacologist and medicinal chemist. [1] Previously the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University, Nichols has worked in the field of psychoactive drugs since 1969. While still a graduate student, he patented the ...